FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to conjugates for the delivery of medications, which bind receptors on the cell surface, containing hydrophilic linker spacers.
EFFECT: claimed conjugates are intended for visualisation, diagnostics and treatment of painful conditions, caused by populations of pathogenic cells.
38 cl, 19 dwg, 49 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATES OF LIGAND AND DRUGS | 2006 |
|
RU2470668C2 |
| POLY-LIGAND MEDICINAL CONJUGATES AND USE THEREOF | 2016 |
|
RU2722449C2 |
| DRUG BILIGAND CONJUGATE AND USE THEREOF | 2020 |
|
RU2820346C2 |
| METHOD FOR TREATING CANCER BY TARGETING SUPPRESSOR CELLS OF MYELOID ORIGIN | 2017 |
|
RU2776899C2 |
| METHODS AND COMPOSITIONS FOR CAR-T-CELL THERAPY | 2017 |
|
RU2792653C2 |
| MONOMETHYLVALINE COMPOUNDS CAPABLE OF FORMING CONJUGATES WITH LIGANDS | 2004 |
|
RU2448117C2 |
| NEW OLIGONUCLEOTIDES CONJUGATES AND USE THEREOF | 2012 |
|
RU2599449C1 |
| BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | 2015 |
|
RU2708459C2 |
| TARGETING AMINOACID LIPIDS | 2013 |
|
RU2654210C2 |
| CONJUGATES FOR DELIVERY OF POLYNUCLEOTIDES IN VIVO, CONTAINING BONDS SENSITIVE TO ENZYMATIC DEGRADATION | 2011 |
|
RU2619453C2 |
